Overview
Yes. Beyond weight loss, Wegovy® (semaglutide), available through MedExpress, has been shown to offer significant protection for the cardiovascular system, particularly for people at higher risk of heart-related problems.
Use this article when you want to:
Understand how Wegovy® reduces the risk of serious heart events
Learn about Wegovy®'s impact on obesity-related heart failure
Find out why Wegovy® is considered a landmark treatment for heart health
Reducing Cardiovascular Risk
Clinical data has demonstrated that Wegovy® can reduce the risk of heart attack, stroke, or cardiovascular death by approximately 20%. These benefits were seen in adults with overweight or obesity who already had established heart disease, even if they did not have diabetes.
Wegovy® is thought to protect the heart through two main pathways:
Sustained weight loss: Supporting a healthy, lower body weight reduces the overall strain on the heart and blood vessels.
Direct heart function: Emerging evidence suggests Wegovy® works directly to improve how the heart functions biologically.
Improving Heart Failure Symptoms
For people living with obesity-related heart failure, Wegovy® has been shown to improve daily symptoms and increase exercise capacity. This means patients taking Wegovy® may find it easier to stay active, and experience less shortness of breath or fatigue during physical exertion.
A Landmark Approval
Because of these proven cardiovascular benefits, Wegovy® became the first weight-loss medication approved specifically to help prevent heart attacks and strokes in adults with overweight or obesity who have existing heart disease. This makes Wegovy® a unique option for people managing both their weight and their long-term heart health.
Need Further Support?
If you still need help after reviewing the information above, additional assistance is available.